

MARKET ANNOUNCEMENT

Continuous Disclosure

Sydney, August 07, 2014 – Integrated Research (“IR”) is in the early stages of preparing its financial statements for the year ending 30 June 2014. Based on internal management accounts and subject to audit review, the Company’s unaudited accounts indicate a revenue increase of 9% to \$53.2 million when compared to the prior year. Profit after tax is anticipated to be in the range of \$8.3 million to \$8.7 million compared to the prior year of \$9.1 million.

After reporting a strong 1st half performance, the momentum did not continue through the second half primarily due to the absence of large licence sale contracts in the second half of FY14, highlighting the lumpiness of the business. The large deal pipeline remains strong. The reported Gross Domestic Product for the United States fell 2.1% in Q1 CY2014; the United States is Integrated Research’s major market.

The result was impacted by management’s investment in key business initiatives including expanding the European and Asia Pacific operations together with increasing investment focus in the evolving Microsoft Lync and Contact Centre markets.

This statement is made for market guidance. IR does not expect to make any further comment until the accounts have been finalised and approved for release to the ASX (anticipated announcement date: 14 August 2014).

By authority of the Board
Darc Rasmussen
Chief Executive Officer
Integrated Research Limited
ABN: 76 003 588 449

- ends -

About Integrated Research (IR) – IR is a leading global provider of high availability performance monitoring, business intelligence and diagnostic software. The creator of award-winning Prognosis® - IR builds scalable, customizable solutions designed to manage continuity-critical IT infrastructure, payments and communications ecosystems. IR provides real time solutions that give customers the insight they need to run their businesses, reduce their operating costs, minimize risk, and gain competitive advantage.

For further information on Integrated Research and Prognosis, visit www.ir.com.